AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
CONMED Corporation
Video analysis: CNMD
All videosNo video analysis for this stock yet. Request one from our team.
News: CNMD
Canada Pension Plan Investment Board Buys Shares of 13,800 CONMED Corporation $CNMD
Canada Pension Plan Investment Board purchased a new position in CONMED Corporation (NYSE: CNMD) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 13,800 shares of the company's stock, valued at approximately $452,000. Other institutional investors also recently modified
Conmed (CNMD) Up 7.1% Since Last Earnings Report: Can It Continue?
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?
CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its participation in the Wells Fargo 21st Annual Healthcare Conference, which is being held September 8-10, 2026 at the Encore Boston Harbor in Everett, MA. Management will participate in a fireside chat on Wednesday, September 9th at 1:30 p.m. Eastern Time. A live audio webcast of the fireside chat will be accessible under the “Events” section of the company's investor relations website: https://www.conmed.com/en/inv.
CONMED Corporation: Organic Growth Is Masked By Divestitures
Conmed's headline growth appeared flat at $343 million in the last quarter, but organic growth actually increased by 6%, with the leading segment being the orthopedic surgery business. Growth was offset by the divestiture of the GI business; as a result, growth metrics look poor with a quant rating of F and below the sector growth. When I adjust for organic growth, impressive profitability, and a buyback story, Conmed stock looks highly undervalued below the sector multiple. and I am rating it a buy.
CNMD Jumps 16% in a Month as Investors Assess Whether It Can Last
CNMD's 16% monthly rally is backed by stronger growth, margin gains and raised earnings guidance, but cash-flow and execution risks remain.
Can CONMED's Raised 2026 EPS Outlook Reinforce Its Growth Momentum?
CONMED raised its 2026 adjusted EPS outlook after a strong second quarter, but slower organic growth and higher financing costs keep the setup mixed.
Is CNMD a Buy Now as Low Valuation Meets Persistent Execution Risk?
CNMD's low valuation and improved earnings outlook strengthen its appeal, but cash-flow pressure and execution risks keep the buy case measured.
Here's Why You Should Retain CONMED Stock in Your Portfolio Now
CONMED's growth outlook is supported by Buffalo Filter, BioBrace and organic momentum, though slower AirSeal growth and tariffs remain key risks.
